Phenotypic Precision Medicine in Advanced Prostate Cancer
Advertisement
Latest News
Video Interviews
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Professor Bex discusses the phase II NEOAVAX trial that evaluated avelumab/axitinib as neoadjuvant therapy in localized RCC.
Samer Srour, MB, talks about the updated ALLO-316 and its use in targeting CD70 in patients with advanced ccRCC.
Dr. Flavell discusses how landmark studies have shaped current trial designs, and growing interest in combination therapies.
Dr. Flavell highlights the expansion of lutetium PSMA therapies into earlier disease settings: HSPC and oligometastatic PC.
Preliminary trial data suggests that 18F-DCFPyL PSMA PET/CT combined with mpMRI may improve csPCA detection over MRI alone.
Quantitative analysis outperformed visual analysis in the prediction of outcomes for patients undergoing Lu-PSMA therapy.
Advertisement
Advertisement
Trending
Rana McKay, MD, GU Medical Oncologist from UCSD, gives her outlook on the future of prostate cancer care in the year 2025.
An extra 2 chemotherapy cycles in patients with advanced urothelial carcinoma didn't reduce tumor size in most cases.
Nanobubbles can target membrane proteins, including PSMA, to bind to receptors that are overexpressed in cancer cells.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.